Clearpoint Neuro is trading 19% down at $12.41 after its August 3 earnings report revealed a wider-than-expected quarterly loss and a downward revision to full-year 2026 revenue guidance.
- Although revenue grew 18% year-over-year to $10.9 million, performance was hampered by weakness in the Biologics and Drug Delivery segment.
- Sentiment has shifted as investors reassess growth and risk following more cautious expectations for partner-driven gene therapy timelines.